Emerging Markets to Drive the Growth of Biopharmaceuticals in the Next Five Years

Delhi, India-- (SBWire) -- 11/04/2010 -- According to Imarc’s latest research report, “Global Biopharmaceutical Market Report (2010-2015)”, biopharmaceutical sales in the seven emerging markets- Russia, China, Turkey, Mexico, South Korea, India and Brazil will more than triple from the current US$ 4.5 billion to more than US$ 13.6 billion by 2015.

According to the report, the top eight markets (United States, Japan, Germany, France, Italy, Spain, United Kingdom and Canada) represent the key markets for biopharmaceutical manufacturers and accounted for nearly 83% of the total global biopharmaceutical sales in 2009. Analysts from Imarc predict that growth rates in these markets will be restrained by a number of factors such as biosimilar entry and increasing cost containment measures. Although the eight major markets will continue to be key markets in the distant future, manufacturers will have to look for newer unpenetrated markets for continued success.

As per the research findings, the treatment costs associated with biopharmaceuticals are extremely high and at times can exceed hundreds of thousands of dollars a year. Since most of the healthcare costs in the emerging markets are paid out-of-pocket, most patients cannot afford these treatments. However, the seven emerging markets taken together account for more than three billion people, representing more than 45% of the total Global population. So even if a small percentage of patients are able to afford these drugs, it still represents a huge market potential. Moreover, the GDPs of emerging markets have witnessed strong growth during the last few years, and this is likely to continue in the coming years as well. This is expected to create a huge middle class that can afford innovative treatments.

The report also suggests that despite the huge opportunity, these markets will not be easy for western manufacturers to penetrate. A major challenge for manufacturers entering these markets is the fact that emerging markets are more complex and different from the developed markets as well as from each other. A strategy that will work in Turkey will not work well in India or China. Manufacturers will have to devise strategies, customized as per the requirements of the individual markets.

IMARC’s new report “Global Biopharmaceutical Market Report (2010-2015)” gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure, therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2015.

Table of Contents

1. Market Definitions & Research Methodology
2. Analyst Briefing
3. Introduction to Biopharmaceuticals
4. Global Biopharmaceutical Market: Industry Analysis
4.1 Strengths
4.1.1 High Efficacy and Target Oriented Attack
4.1.2 Strong Potential to Achieve Blockbuster Status
4.1.3 Limited Generic Threat
4.1.4 Approval Success Rates are Higher than Small Molecule Drugs
4.2 Weaknesses
4.2.1 Inconvenient Drug Delivery Coupled with Short Half Lives
4.2.2 Second Line of Therapy
4.2.3 Huge Cost of Therapy
4.2.4 High Incidence of Unfavorable Side Effects
4.3 Opportunities
4.3.1 Diseases with High Unmet Needs
4.3.2 Expanding the Patient Pool by Approval into Additional Indications
4.3.3 Emerging Markets
4.3.4 Increasing New Approvals and a Strong Pipeline
4.4 Threats
4.4.1 Biopharmaceutical Drug Development is a Very Risky Venture
4.4.2 Biosimilars
4.4.3 Limited and Conditional Reimbursement
4.4.4 Uncertainties in the Economic Environment
5. Global Biopharmaceutical Market: Industry Performance
5.1 Market Performance & Forecast
5.1.1 Current Performance (2005-2009)
5.1.2 Market Forecasts (2010-2015)
5.2 Market Segmentation by Region
5.2.1 Current Performance (2005-2009)
5.2.2 Market Forecasts (2010-2015)
5.3 Market Segmentation by Indication
5.4 Market Segmentation by Class
5.4.1 Recombinant Proteins
5.4.1.1 Current Performance (2005-2009)
5.4.1.2 Market Forecasts (2010-2015)
5.4.2 Monoclonal Antibodies
5.4.2.1 Current Performance (2005-2009)
5.4.2.2 Market Forecast (2010-2015)
5.4.3 Purified Proteins
5.4.3.1 Current Performance (2005-2009)
5.4.3.2 Market Forecast (2010-2015)
5.5 Competitive Landscape
5.5.1 Top Biopharmaceutical Players
5.5.2 Top Biopharmaceutical Drugs
6. North America
6.1 US
6.1.1 Market Performance (2005-2009)
6.1.2 Market Segmentation by Class
6.1.3 Performance of Top Players
6.1.4 Market Forecasts (2010-2015)
6.2 Canada
6.2.1 Market Performance (2005-2009)
6.2.2 Market Segmentation by Class
6.2.3 Performance of Top Players
6.2.4 Market Forecasts (2010-2015)
7. Latin America
7.1 Mexico
7.1.1 Market Performance (2005-2009)
7.1.2 Market Segmentation by Class
7.1.3 Performance of Top Players
7.1.4 Market Forecasts (2010-2015)
7.2 Brazil
7.2.1 Market Performance (2005-2009)
7.2.2 Market Segmentation by Class
7.2.3 Performance of Top Players
7.2.4 Market Forecasts (2010-2015)
7.3 Argentina
7.3.1 Market Performance (2005-2009)
7.3.2 Market Segmentation by Class
7.3.3 Performance of Top Players
7.3.4 Market Forecasts (2010-2015)
8. Europe
8.1 Germany
8.1.1 Market Performance (2005-2009)
8.1.2 Market Segmentation by Class
8.1.3 Performance of Top Players
8.1.4 Market Forecasts (2010-2015)
8.2 France
8.2.1 Market Performance (2005-2009)
8.2.2 Market Segmentation by Class
8.2.3 Performance of Top Players
8.2.4 Market Forecasts (2010-2015)
8.3 Italy
8.3.1 Market Performance (2005-2009)
8.3.2 Market Segmentation by Class
8.3.3 Performance of Top Players
8.3.4 Market Forecasts (2010-2015)
8.4 Spain
8.4.1 Market Performance (2005-2009)
8.4.2 Market Segmentation by Class
8.4.3 Performance of Top Players
8.4.4 Market Forecasts (2010-2015)
8.5 UK
8.5.1 Market Performance (2005-2009)
8.5.2 Market Segmentation by Class
8.5.3 Performance of Top Players
8.5.4 Market Forecasts (2010-2015)
8.6 Russia
8.6.1 Market Performance (2005-2009)
8.6.2 Market Segmentation by Class
8.6.3 Performance of Top Players
8.6.4 Market Forecasts (2010-2015)
8.7 Turkey
8.7.1 Market Performance (2005-2009)
8.7.2 Market Segmentation by Class
8.7.3 Performance of Top Players
8.7.4 Market Forecasts (2010-2015)
9. Asia Pacific
9.1 Japan
9.1.1 Market Performance (2005-2009)
9.1.2 Market Segmentation by Class
9.1.3 Performance of Top Players
9.1.4 Market Forecasts (2010-2015)
9.2 China
9.2.1 Market Performance (2005-2009)
9.2.2 Market Segmentation by Class
9.2.3 Performance of Top Players
9.2.4 Market Forecasts (2010-2015)
9.3 Australia
9.3.1 Market Performance (2005-2009)
9.3.2 Market Segmentation by Class
9.3.3 Performance of Top Players
9.3.4 Market Forecasts (2010-2015)
9.4 South Korea
9.4.1 Market Performance (2005-2009)
9.4.2 Market Segmentation by Class
9.4.3 Performance of Top Players
9.4.4 Market Forecasts (2010-2015)
9.5 India
9.5.1 Market Performance (2005-2009)
9.5.2 Market Segmentation by Class
9.5.3 Performance of Top Players
9.5.4 Market Forecasts (2010-2015)
9.6 Indonesia
9.6.1 Market Performance (2005-2009)
9.6.2 Market Segmentation by Class
9.6.3 Performance of Top Players
9.6.4 Market Forecasts (2010-2015)

To get the full version of “Global Biopharmaceutical Market Report (2010-2015)” please get in touch with us by emailing us at sales@imarcgroup.com or by calling us on +91-11-43095788